Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943550 · ClinicalTrials.gov registry record · Phase 1
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT03943550 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 45 participants.
The verdict
NCT03943550, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG RO7049665
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2021-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943550
The ClinicalTrials.gov registry entry for NCT03943550 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03943550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943550 about?
NCT03943550 is a clinical study titled "Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)". The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis (UC).
What is the current status of trial NCT03943550?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2019-05-13. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT03943550?
The interventions under investigation include: Placebo (DRUG), RO7049665 (DRUG).
Who is sponsoring clinical trial NCT03943550?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.